Spotlight On... Shire, Baxalta in late-stage talks on $32B tie-up: Bloomberg; Hikma wins FDA approval for surgery recovery drug; NICE does about-face on Merck's Ezetrol; and more...

Shire ($SHPG) is finally nearing the Baxalta ($BXLT) buyout it's long coveted, according to Bloomberg's sources. The two drugmakers are discussing a price between $46.50 and $48 per share, the news service reports, which would value the Illinois pharma at about $32 billion. A tie-up, Shire CEO Flemming Ornskov has said, would create a global rare-disease leader that can bring in $20 billion in sales by 2020. More from FiercePharma

> Hikma Pharmaceuticals has won FDA approval to market a drug used to enable patients to recover from surgery. Release

> U.K. cost-effectiveness gatekeepers have changed their tune when it comes to using Merck's ($MRK) hypercholesterolemia med Ezetrol on the National Health Service, reverting back to original guidelines published in 2007. More

And Finally... Some say the three-year cancer battle of Mary Pazdur, wife of FDA oncology chief Richard Pazdur, increased his willingness to quickly approve risky new therapies. More (sub. req.)


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.